{
    "pmcid": "9651861",
    "qa_pairs": {
        "What future direction is suggested for improving the designed antibodies?": [
            "Enhancing their rigidity for better structural characterization",
            "Increasing their molecular weight for improved stability",
            "Reducing their immunogenicity to minimize side effects",
            "Decreasing their production cost for widespread use"
        ],
        "What is a key advantage of the computational pipeline described in the study?": [
            "It can run on standard laptops and rapidly generate lead antibodies",
            "It requires high-performance computing clusters for execution",
            "It necessitates high-resolution structural data for accuracy",
            "It involves extensive laboratory screening for validation"
        ],
        "What is the primary target of the nanobodies designed in the study?": [
            "The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein",
            "The nucleocapsid protein of SARS-CoV-2",
            "The membrane protein of SARS-CoV-2",
            "The envelope protein of SARS-CoV-2"
        ],
        "What is the significance of the nanobodies' ability to compete with ACE2 for binding to the RBD?": [
            "It suggests they could effectively block the virus's entry into cells",
            "It indicates they have low binding affinity for the RBD",
            "It demonstrates they are unable to neutralize the virus",
            "It shows they require further optimization for therapeutic use"
        ],
        "Which computational method is used to design the nanobodies in the study?": [
            "Fragment-based strategy for designing complementarity-determining regions (CDRs)",
            "Molecular dynamics simulations for protein folding",
            "Machine learning algorithms for sequence prediction",
            "Quantum mechanical calculations for energy minimization"
        ]
    }
}